Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Singh, Indrajeet
Sathe, Abhishek G.
Singh, Pratap
Diderichsen, Paul M.
Fauchet, Floris
Maringwa, John
Pierrillas, Philippe
Phan, See-Chun
Girish, Sandhya
Othman, Ahmed A.
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Certara USA Inc, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1076
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study
    Weide, Rudolf
    Bardia, Aditya
    Tolaney, Sara
    Loirat, Delphine
    Punie, Kevin
    Oliveira, Mafalda
    Rugo, Hope
    Brufsky, Adam
    Kalinsky, Kevin
    Cortes, Javier
    O'shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa
    Gianni, Luca
    Piccart-Gebhart, Martine
    Loibl, Sibylle
    Zhu, Yanni
    Phan, See-Chun
    Hurvitz, Sara
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 37 - 37
  • [32] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [33] Sacituzumab govitecan-a new therapy for patients with triple-negative breast cancer
    Pogoda, Katarzyna
    Jagiello-Gruszfeld, Agnieszka
    Niwinska, Anna
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (01): : 43 - 49
  • [34] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Sathe, Abhishek G.
    Singh, Indrajeet
    Singh, Pratap
    Diderichsen, Paul M.
    Wang, Xiaohui
    Chang, Peter
    Taqui, Atiya
    Phan, See
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
  • [35] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Cheng, Shao-Xian
    Chen, Qiu-Chi
    Lin, Guo-He
    Han, Yan-Hong
    Wang, Bi-Cheng
    Dai, Yi
    Zhao, Yan-Xia
    MEDICINE, 2023, 102 (30) : E34486
  • [36] Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial
    Xu, B.
    Ma, F.
    Wang, S.
    Tong, Z.
    Li, W.
    Wu, X.
    Wang, X.
    Sun, T.
    Pan, Y.
    Yao, H.
    Wang, X.
    Luo, T.
    Yang, J.
    Zeng, X.
    Zhao, W.
    Cong, X. J.
    Wang, N.
    Xu, C.
    Chen, J. J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1438 - S1438
  • [37] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
  • [38] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Abhishek G. Sathe
    Indrajeet Singh
    Pratap Singh
    Paul M. Diderichsen
    Xiaohui Wang
    Peter Chang
    Atiya Taqui
    See Phan
    Sandhya Girish
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2024, 63 : 669 - 681
  • [39] Efficacy of Sacituzumab Govitecan (SG) in Patients with metastatic triple negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Results from the Phase 3 ASCENT Study
    Hegewisch-Becker, S.
    Hurvitz, S. A.
    Bardia, A.
    Punie, K.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Carey, L. A.
    Rugo, H. S.
    Yoon, O. K.
    Pan, Y.
    Delaney, R.
    Hofsess, S.
    Hodgkins, P.
    Phan, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 104 - 105
  • [40] Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Bardia, A.
    Tolaney, S. M.
    Punie, K.
    Loirat, D.
    Oliveira, M.
    Kalinsky, K.
    Zelnak, A.
    Aftimos, P.
    Dalenc, F.
    Sardesai, S.
    Hamilton, E.
    Sharma, P.
    Recalde, S.
    Gil, E. C.
    Traina, T.
    O'Shaughnessy, J.
    Cortes, J.
    Tsai, M.
    Vahdat, L.
    Dieras, V
    Carey, L. A.
    Rugo, H. S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1148 - 1156
12345